CN110959862B - Composition with functions of removing trimethylamine oxide and resisting inflammation and preparation method and application thereof - Google Patents
Composition with functions of removing trimethylamine oxide and resisting inflammation and preparation method and application thereof Download PDFInfo
- Publication number
- CN110959862B CN110959862B CN201911114374.5A CN201911114374A CN110959862B CN 110959862 B CN110959862 B CN 110959862B CN 201911114374 A CN201911114374 A CN 201911114374A CN 110959862 B CN110959862 B CN 110959862B
- Authority
- CN
- China
- Prior art keywords
- strain
- eha2
- lactobacillus reuteri
- tmao
- curcumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- UYPYRKYUKCHHIB-UHFFFAOYSA-N trimethylamine N-oxide Chemical compound C[N+](C)(C)[O-] UYPYRKYUKCHHIB-UHFFFAOYSA-N 0.000 title claims abstract description 59
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 20
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 20
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 91
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 49
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 49
- 235000012754 curcumin Nutrition 0.000 claims abstract description 45
- 229940109262 curcumin Drugs 0.000 claims abstract description 45
- 239000004148 curcumin Substances 0.000 claims abstract description 45
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 45
- 239000006228 supernatant Substances 0.000 claims abstract description 40
- 238000000855 fermentation Methods 0.000 claims abstract description 33
- 230000004151 fermentation Effects 0.000 claims abstract description 33
- 239000007788 liquid Substances 0.000 claims description 18
- 230000003213 activating effect Effects 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 230000000813 microbial effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 230000002757 inflammatory effect Effects 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 230000003143 atherosclerotic effect Effects 0.000 abstract description 7
- 230000003993 interaction Effects 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 23
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
- 239000000523 sample Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 13
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical group CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 238000010839 reverse transcription Methods 0.000 description 6
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 5
- 235000010633 broth Nutrition 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 238000007664 blowing Methods 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- -1 tincture Substances 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000209524 Araceae Species 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 102100035041 Dimethylaniline monooxygenase [N-oxide-forming] 3 Human genes 0.000 description 1
- 101710187736 Dimethylaniline monooxygenase [N-oxide-forming] 3 Proteins 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 101000953909 Streptomyces viridifaciens Isobutylamine N-hydroxylase Proteins 0.000 description 1
- 101710116896 Trimethylamine methyltransferase MttB Proteins 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- PVBQYTCFVWZSJK-UHFFFAOYSA-N meldonium Chemical compound C[N+](C)(C)NCCC([O-])=O PVBQYTCFVWZSJK-UHFFFAOYSA-N 0.000 description 1
- 229960002937 meldonium Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Botany (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a composition with functions of removing trimethylamine oxide and resisting inflammation, and a preparation method and application thereof. The composition comprises curcumin and/or lactobacillus reuteri EHA2 strain. The research of the invention finds that after the interaction between the curcumin and/or the fermentation supernatant of the Lactobacillus reuteri EHA2 strain and the TMAO, the content of the TMAO in the solution can be reduced, and meanwhile, the expression level of inflammatory factors can be obviously reduced by the curcumin and/or the fermentation supernatant of the Lactobacillus reuteri EHA2 strain. The composition can eliminate TMAO and inflammation caused by TMAO, has the effect of relieving atherosclerotic diseases, and has good social and economic benefits.
Description
Technical Field
The invention relates to the technical field of biological medicines, and in particular relates to a composition with functions of removing trimethylamine oxide and resisting inflammation, and a preparation method and application thereof.
Background
Atherosclerotic disease (AS) is one of the diseases with high worldwide morbidity and mortality, and since atherosclerosis has long been considered to be a disease caused by lipid deposition on the arterial wall, conventional treatments have been directed to lowering blood lipid and blood pressure. However, cardiovascular disease due to atherosclerosis remains high, causing millions of deaths worldwide each year. Today, the atherosclerotic concept has been gradually replaced by a lipid-driven, chronic inflammatory disease of the arterial wall. More and more studies have confirmed that there is a close relationship between the intestinal flora and cardiovascular disease. The intestinal flora can metabolize food containing trimethylamine structure to produce Trimethylamine (TMA), and further be oxidized by flavin-monooxygenase 3 (FMO 3) to produce trimethylamine oxide (TMAO) on the liver, and the TMAO can promote vascular inflammation and accelerate the development process of AS through various signal pathways. Therefore, blocking the production of TMAO and down-regulating this inflammatory signaling pathway may be regarded as an effective strategy to intervene in cardiovascular inflammation and thus prevent and treat atherosclerosis.
Only chinese patent 201380041723.X discloses a pharmaceutical composition for reduction of trimethylamine N-oxide levels in humans comprising 3- (2, 2, 2-trimethylhydrazinium) propionate (meldonium) as an active ingredient, and a pharmaceutically acceptable carrier; chinese patent 201380069004.9 discloses a composition comprising a microorganism, preferably archaea, which expresses TMA methyltransferase and TMA methyl group receptor corrinoid protein, which is capable of undergoing Trimethylamine (TMA) metabolism in a human compartment in the presence of hydrogen, such as the gut or vagina, as a medicament for treating, reducing or eliminating TMA in the human compartment; chinese patent 201810889757.9 discloses the application of berberine in preparing medicine for preventing and treating vascular endothelial dysfunction. The few compositions which are reported to reduce the level of trimethylamine oxide in human body are still available, and especially the compositions which directly remove the trimethylamine oxide and have anti-inflammatory function are not reported.
Disclosure of Invention
The invention aims to overcome the defects and shortcomings in the prior art and provide a composition with functions of removing trimethylamine oxide and resisting inflammation.
It is another object of the present invention to provide a method for preparing said composition.
It is a further object of the present invention to provide the use of said composition.
The above object of the present invention is achieved by the following technical solutions:
the research of the invention finds that after the interaction between the curcumin and/or the fermentation supernatant of the Roy's lactobacillus EHA2 strain and the TMAO, the content of the TMAO in the solution can be reduced, and particularly, the content of the TMAO in the solution can be obviously reduced by the composition of the curcumin and the fermentation supernatant of the Roy's lactobacillus EHA2 strain which are mixed according to a specific proportion. And simultaneously, after the human vascular smooth muscle cells are pretreated by fermenting the supernatant of the curcumin and/or the Lactobacillus reuteri EHA2 strain, the human vascular smooth muscle cells are intervened by TMAO. The results show that compared with the method of directly using TMAO to intervene human vascular smooth muscle cells without using curcumin or fermentation supernatant of Lactobacillus reuteri, the expression level of the inflammatory factors of the human vascular smooth muscle cells after the pre-drying prognosis of the curcumin or fermentation supernatant of the Lactobacillus reuteri EHA2 strain is remarkably reduced, and particularly the expression level of the inflammatory factors of the pre-drying prognosis of the fermentation supernatant of the curcumin and the Lactobacillus reuteri EHA2 strain is most remarkably reduced. The results show that the fermentation supernatant of curcumin and/or lactobacillus reuteri EHA2 strain has functions of removing trimethylamine oxide and resisting inflammation.
Therefore, the invention firstly protects the application of the curcumin and/or the lactobacillus reuteri EHA2 strain in preparing the pharmaceutical preparation with functions of removing the trimethylamine oxide and resisting inflammation.
A composition with functions of eliminating trimethylamine oxide and anti-inflammatory comprises flavin and/or Lactobacillus reuteri EHA2 strain; the lactobacillus reuteri EHA2 strain is preserved in Guangdong province microorganism strain preservation center in 2019, 9, 2, with the preservation number of GDMCC NO: 60758.
preferably, the composition comprises a flavin and/or a fermentation supernatant of lactobacillus reuteri EHA2 strain.
Preferably, the composition comprises the following components in volume ratio: the curcumin solution and fermentation supernatant of lactobacillus reuteri EHA2 strain are 1-3: 1 to 3.
More preferably, the composition comprises the following components in volume ratio: curcumin solution and lactobacillus reuteri EHA2 strain fermentation supernatant ═ 1: 3; the curcumin solution and the lactobacillus reuteri composition in the proportion have the best effect of removing TMAO.
Preferably, the concentration of the curcumin solution is 40-300 mM.
The fermentation liquor of the strain of lactobacillus reuteri EHA2 is prepared according to the conventional preparation method of the fermentation liquor of lactobacillus reuteri in the field. Preferably, the preparation method of the fermentation supernatant of the lactobacillus reuteri EHA2 strain comprises the steps of activating the strain of lactobacillus reuteri EHA2, inoculating the activated strain into a fermentation medium, fermenting for 40-50 h (preferably 48h) at 30-37 ℃ (preferably 37 ℃), adjusting OD of the fermented bacterial liquid to 1.6-1.8 (preferably 1.8), centrifuging, and reserving the supernatant to obtain the fermentation supernatant of the lactobacillus reuteri EHA2 strain.
Preferably, the activation medium is MRS solid medium, and the strain activation time is 37 ℃ for culturing for 48 h; the fermentation medium is MRS broth.
Preferably, the centrifugation is 5000-7000 r/min, 0-4 ℃, and 10-15 min (preferably 6000r/min, 4 ℃, and 15 min).
The invention also claims the application of the composition in preparing a preparation with functions of removing trimethylamine oxide and resisting inflammation.
The application of the composition in preparing a preparation for preventing and treating atherosclerotic diseases and/or cardiovascular diseases.
Preferably, the formulation is a tablet, capsule, powder, oral liquid, soft capsule, pill, tincture, syrup, suppository, gel, spray, umbilical patch, effervescent tablet or injection.
A preparation for eliminating trimethylamine oxide and anti-inflammatory function comprises fermentation supernatant of flavin and/or Lactobacillus reuteri EHA2 strain.
Preferably, the preparation method of the preparation comprises the following steps: weighing the raw material components according to the volume ratio, and dissolving the raw material components in water with the volume multiple of 80-100 to obtain the preparation with functions of removing trimethylamine oxide and resisting inflammation. Curcumin is a chemical component extracted from rhizomes of some plants in Zingiberaceae and Araceae, is a pigment with diketone which is rare in plant world, and is a diketone compound. Curcumin is orange yellow crystal powder, slightly bitter in taste and insoluble in water, is mainly used for coloring sausage products, cans, sauced and marinated products and other products in food production, and has the effects of reducing blood fat, resisting tumors, benefiting gallbladder, resisting oxidation and the like. The lactobacillus reuteri is intestinal probiotics which can improve the functions of human bodies and improve the immunity, so that the human safety of the preparation can be ensured.
The composition can eliminate TMAO and inflammation caused by TMAO, can be used for relieving atherosclerotic diseases and cardiovascular diseases, and has good social and economic benefits.
Compared with the prior art, the invention has the following beneficial effects:
the invention provides a composition with functions of removing trimethylamine oxide and resisting inflammation, and after the composition interacts with TMAO, the content of TMAO in a solution can be reduced, and the expression level of inflammatory factors can be obviously reduced. The composition can eliminate TMAO and inflammation caused by TMAO, has the effect of relieving atherosclerotic diseases, and has good social and economic benefits.
Drawings
FIG. 1 is a standard curve for TMAO content analysis established by the present invention.
FIG. 2 shows that TMAO is used to intervene the expression effect of human vascular smooth muscle cells 6h on inflammatory factors in human vascular smooth muscle cells after the human vascular smooth muscle cells are intervened in advance for 6h in different pretreatment modes.
Detailed Description
The invention is further described with reference to the drawings and the following detailed description, which are not intended to limit the invention in any way. Reagents, methods and apparatus used in the present invention are conventional in the art unless otherwise indicated.
Unless otherwise indicated, reagents and materials used in the following examples are commercially available.
Example 1 isolated culture of Lactobacillus reuteri EHA2 and preparation of fermentation broth
1. Media preparation
MRS solid medium: 10.0g of peptone, 8.0g of beef powder, 4.0g of yeast powder, 20.0g of glucose, 2.0g of dipotassium phosphate, 5.0g of sodium acetate, 2g of diammonium citrate, 0.2g of magnesium sulfate, 0.05g of manganese sulfate, 801 g of tween, 15g of agar, 1L of water and high-pressure sterilization at 121 ℃ for 15 min;
MRS broth culture medium: 10.0g of peptone, 8.0g of beef powder, 4.0g of yeast powder, 20.0g of glucose, 2.0g of dipotassium phosphate, 5.0g of sodium acetate, 2g of diammonium citrate, 0.2g of magnesium sulfate, 0.05g of manganese sulfate, 1L of water in 801 g of Tween, and autoclaving at 121 ℃ for 15 min.
2. Isolated culture of Lactobacillus reuteri EHA2 strain
(1) Preparation of bacterial suspension
Firstly, stirring human intestinal excrement uniformly, sucking 10mL of a sample by using a sterile pipette, adding the sample into a triangular flask containing 90mL of sterile water, and fully shaking for 20 minutes on a vortex homogenizer to uniformly disperse the sample. A1 mL sterile pipette is used for sucking 1mL of the fecal bacterial liquid suspension from the tube, injecting the fecal bacterial suspension into a 9mL test tube of sterile water, and blowing the tube for three times to ensure that the fecal bacterial suspension is fully and uniformly mixed. Then using a 1mL sterile pipette to draw 1mL of the solution from the test tube and inject the solution into another test tube containing 9mL of sterile water, and so on to obtain 10-1、10-2、10-3、10-4、10-5、10-6、10-7Various dilutions of the bacterial suspension (7 mL tubes were taken).
(2) Inverted plate
Taking 12 sterile plates, numbering 10-1、10-5、10-6、10-7Three sets of the components; cooling MRS solid culture medium sterilized at 121 deg.C for 30min to about 65 deg.CPouring 12 plates according to the aseptic technique, wherein each dish is about 15 mL; the culture medium is evenly distributed at the bottom of the dish by flat placement and is to be solidified.
3. Separation method
(1) Marking on a position close to flame, holding the bottom of the dish by the left hand and holding the inoculating ring by the right hand, and marking the flat plate according to aseptic operation.
(2) And (3) selecting a first bacterial liquid ring by using an inoculating ring in an aseptic operation, firstly carrying out primary parallel lineation on one side of a plate culture medium for 3-4 lines, then rotating a culture dish for about 70 degrees, burning the remainder on the inoculating ring, cooling, then carrying out secondary parallel lineation on a first lineation part, and then carrying out third parallel lineation on a second parallel lineation part and carrying out fourth parallel lineation on a third parallel lineation part by using the same method. After the streaking, the dish cover is closed, and the dish cover is placed upside down and cultured in a constant temperature incubator at 37 ℃ for 48 hours. Respectively picking and inoculating single colonies grown after culture to a new MRS solid culture medium, checking whether pure culture is carried out or not, and if not, continuing isolated culture until pure culture is obtained to obtain a pure culture strain EHA 2; gram-positive, rod-shaped, no spore, no movement, milky round, neat edge, and smooth and glossy surface. The optimum growth temperature is 37 ℃, catalase is invisible, and lactose, galactose, maltose, rhamnose and mannose can be hydrolyzed. The 16S rRNA gene of the strain EHA2 is extracted and sequenced, the sequence of the gene is shown as SEQ ID NO.1, and BLAST analysis is carried out on the gene and an NCBI website database, and the result analysis shows that the similarity of the gene and a model strain of the strain Lactobacillus reuteri is the highest, wherein the sequence similarity with the Lactobacillus reuteri strain LQ2 is more than 99%. By combining the physiological and biochemical characteristics and the 16S rRNA gene sequence results, the strain EH132 is identified to belong to Lactobacillus reuteri, the strain is named as Lactobacillus reuteri EHA2(Lactobacillus reuteri EHA2), and the strain is preserved in Guangdong province microbial culture Collection (GDMCC) in 2019, 9 and 2 days, and the address: guangzhou city, Xielizhonglu No. 100 college No. 59 building No. 5, with the preservation number GDMCC NO: 60758.
4. lactobacillus reuteri EHA2 culture method and preparation of fermentation supernatant
Activating strains by adopting an MRS solid culture medium, and culturing for 48 hours in an incubator at 37 ℃; then 2 rings of the activated strain are inoculated into MRS broth and fermented for 48h at 37 ℃. Adjusting the OD of the fermented bacterial liquid to 1.8; centrifuging at 4 deg.C for 15min at 6000r/min, and collecting supernatant.
Example 2 the Effect of curcumin and Lactobacillus reuteri EHA2 fermentation broths on TMAO content
Method and device
1. Preparation of the solution:
(1) TMAO solution: 75.11mg of anhydrous trimethylamine oxide powder was weighed, 10mL of PBS was added, and the mixture was mixed by sonication to obtain 100mM TMAO solution, which was dispensed into 10 EP tubes (1 mL each) each having a concentration of 1.5mL and placed in a refrigerator at-20 ℃.
(2) Curcumin solution: 552.57mg of curcumin powder is weighed, 5mL of DMSO is added and mixed evenly to obtain a curcumin solution with the concentration of 300mM, and the curcumin solution is stored in a refrigerator at the temperature of minus 20 ℃ after being subpackaged.
(3) Preparation of a sample: taking 50 mu L of TMAO solution in the step (1), 200 mu L of fermentation supernatant of the Lactobacillus reuteri EHA2 strain in the example 1 and curcumin solution in the step (2) according to the proportion of 1:1, 1:2, 1:3, 2:1 and 3:1, putting the mixture into a 2mL EP tube together, and reacting for 12 h.
(4) Preparing a TMAO standard solution: TMAO powder was precisely weighed at 5.0mg, and placed in a 50mL EP tube, dissolved and diluted with methanol to a concentration of 100. mu.g/mL, and stored at-20 ℃ after being dispensed.
(5) Preparation of internal standard solution: dissolving d9-TMAO standard product in methanol to obtain 5 μ M methanol solution, packaging, labeling, and storing at-20 deg.C.
(6) And (4) taking 50 mu L of the mixed sample in the step (3) to be detected.
2. And (3) establishing a standard curve, and preparing TMAO standard solutions with the concentrations of 0, 7.8125, 15.625, 31.625, 125, 250, 500, 1000 and 2000ng/mL by using methanol solutions respectively. And (5) sampling to determine peak area and calculating a regression equation of the curve.
3. And substituting the measurement peak area of each plasma sample into a standard regression equation to obtain the plasma TMAO concentration of each sample.
Second, result in
The established standard curve is shown in fig. 1, the detection result is shown in table 1, the curcumin or the fermentation supernatant of the lactobacillus reuteri EHA2 strain has a good effect of removing TMAO, and particularly, after the curcumin, the fermentation supernatant of the lactobacillus reuteri EHA2 strain and the TMAO react together for 12 hours, the ratio of the curcumin to the bacteria supernatant is 1: the maximum cleaning effect on TMAO is achieved at the time of 3.
TABLE 1 curcumin and Lactobacillus reuteri EHA2 fermentation supernatants effects on TMAO levels (triplicates)
| Composition (v/v) | TMAO(ng/mL) | TMAO(ng/mL) | TMAO(ng/mL) |
| Blank group | 244.0 | 243.5 | 244.2 |
| Curcumin (4) | 75.5 | 76.1 | 76.4 |
| Curcumin: mushroom supernatant (2:1) | 73.7 | 71.1 | 73.3 |
| Mushroom supernatant (4) | 70.0 | 68.2 | 68.9 |
| Curcumin: mushroom supernatant (3:1) | 62.8 | 62.5 | 61.6 |
| Curcumin: mushroom supernatant (1:2) | 59.9 | 61.4 | 59.0 |
| Curcumin: mushroom supernatant (1:3) | 55.8 | 53.4 | 53.3 |
Example 3 the Effect of curcumin and Lactobacillus reuteri EHA2 fermentation broths on the expression of smooth muscle cell inflammatory factors
1. Cell pretreatment
(1) Human vascular Smooth Muscle Cells (Human Vasc μ Lar Smooth Muscle Cells, HVSMCs) were sourced from the cardiovascular laboratory gift of the zhajiang hospital, southern medical university.
(2) Culture of HVSMCs
Adherent growth in RPMI1640 medium containing 10% fetal bovine serum at 37 deg.C under 5% CO2And culturing in a cell culture box with fully saturated humidity, and changing the liquid every other day to maintain a good growth state.
(3) And (3) pre-intervening human vascular smooth muscle cells for 6h with or without curcumin or curcumin plus Lactobacillus reuteri supernatant, and intervening human vascular smooth muscle cells for 6h with TMAO.
2. Trizol method for extracting total RNA of vascular smooth muscle cells in each group
Human Vascular Smooth Muscle Cells (HVSMCs) were grown adherent to RPMI1640 medium containing 10% fetal bovine serum at 37 deg.C and 5% CO2And culturing in a cell culture box with completely saturated humidity, and changing the culture solution every 1 day to maintain a good growth state. Cells in good state are put into a 6-well plate for culture, and the medicine is added when the cells are fused to 80-90%. With or without curcumin (concentration 40mM, volume 3. mu.L) or curcumin (concentration 40mM, volume 3. mu.L) plus 9. mu.L (OD) of Lactobacillus reuteri EHA2 supernatant600The nm value is 1.8), intervening human vascular smooth muscle cells for 6 hours in advance, sucking out culture solution in a 6-hole plate, and washing the cells for 2-3 times by using PBS; adding 500 mu L of Trizol into each hole, standing for 5min on ice, repeatedly blowing and beating the bottom of the dish by using an enzyme-free gun head to fully and uniformly mix the cells with the Trizol, and facilitating further cell lysis. The cell lysate was then transferred to a 1.5mL EP tube. If the time is not enough for subsequent operation, the EP tube filled with the cell lysate can be placed in a refrigerator at minus 80 ℃ for short-term storage and standby. If RNA in blood vessels is extracted, 20-40 mg of tissue is weighed and placed into a 1.5mL EP tube, 1mL of Trizol is added after shearing, and 60HZ lysis is carried out on a homogenizer for 120 s.
(2) To each 1.5mL of EP tube was added 200. mu.L of chloroform (chloroform), the lid of the EP tube was closed, and the solution was mixed well to pink by vigorous shaking on a shaker for 1 min. After standing on ice for 10min, the mixture was centrifuged at 12000g for 15min at 4 ℃.
(3) After the centrifugation is finished, the centrifuge tube is taken out, and a sample is divided into three layers, namely an upper colorless water phase, a white middle layer and a bottom organic phase, wherein RNA is mainly located in the upper water phase, and the volume of the water phase is about 40% of the dosage of Trizol. Carefully sucking 100-200 mu L of upper-layer aqueous phase liquid, and avoiding contacting with the middle-layer liquid and the lower-layer liquid in the sucking process. If the operation carelessly sucks the liquid in the lower two layers, the centrifugation is carried out once under the same condition, and the liquid in the upper layer is carefully and slowly sucked. The supernatant liquid was transferred to a new enzyme-free 1.5mL EP tube.
(4) Adding isopropanol with the volume equal to that of the liquid absorbed in the step (3), slightly inverting the EP tube from top to bottom and from left to right to mix the liquid uniformly, moving the liquid to ice, standing for 5min, and centrifuging for 10min in a centrifuge with the conditions of 4 ℃ and 12000 g.
(5) The supernatant was decanted and the EP tube was inverted on a paper towel to leave no residual isopropanol on the tube wall and white RNA precipitate was visible at the bottom of the tube.
(6) And respectively adding 500 mu L of precooled 75% ethanol into each tube, and slightly reversing the EP tube from top to bottom and from left to right for 8-10 times so as to facilitate the ethanol to dissolve the residual isopropanol and achieve the purpose of washing RNA precipitates. Centrifuge at 7500g for 5min at 4 ℃, then discard the supernatant and reverse-thread the EP tube on a paper towel so that no liquid remains on the tube wall.
(7) The EP tube was removed from the hood, the lid opened to allow ethanol to evaporate sufficiently, and the RNA pellet dried. After 5min, adding a proper amount of sterile enzyme-free water to dissolve the RNA precipitate, and before measuring the RNA concentration, blowing and stirring the mixed liquid.
(8) The RNA concentration was determined by first zeroing the SimpliNano detector with 2. mu.L of sterile, enzyme-free water and repeating 2 times.
(9) After the zero calibration is completed, the genome RNA concentration of each sample is sequentially detected, each sample is repeatedly measured for 2 times, and the recorded data is averaged. The purity of each sample is referred to by the ratio of EHA260 to EHA280, and the ratio is 1.8-2.0, which represents that the RNA purity of the sample is high. The detected RNA sample can be stored in a refrigerator at-80 ℃ for several weeks for reverse transcription. To avoid RNA degradation, reverse transcription should be performed as early as possible after the sample RNA concentration is determined.
2. Reverse transcription of genomic RNA into cDNA for each sample
(1) Mu.g of RNA are taken from each group and reverse transcribed into cDNA, the required sample volume can be as VVolume of RNA(μL)＝1000ng/CRNA concentration(ng/. mu.L) calculation.
(2) The composition of the reverse transcription 20. mu.L reaction system is shown in Table 2 below:
TABLE 2
(3) The conditions of reverse transcription on the computer are as follows: 15min at 37 ℃; 5s at 85 ℃; 4 ℃ and infinity.
(4) After the reverse transcription reaction is finished, each sample is diluted by sterile enzyme-free water according to the proportion of 1:4 and is uniformly mixed for use. The cDNA can be stored in a refrigerator at-20 ℃.
3. Real-time fluorescent quantitative PCR reaction for detecting expression quantity of inflammatory factor
(1) Primer sequences for inflammatory factors are shown in table 3 below:
TABLE 3
(2) The composition of the RT-PCR 20. mu.L reaction system is shown in Table 4:
TABLE 4
(4) The RT-PCR on-machine reaction conditions are as follows in sequence: pre-denaturation at 95 ℃ for 15 min; denaturation at 95 ℃ for 15 s; annealing, extending at 60 ℃, and performing 40-50 cycles.
(5) Calculation method
And (3) obtaining CT values of each group by RT-PCR, taking beta-actin as a reference gene, and carrying out relative quantification on the expression quantity of each group of target genes by a Livak method. The calculation method is as follows:
Δ CT control group ═ CT (control group, target gene) -CT (control group, reference gene)
Δ CT experimental group ═ CT (experimental group, target gene) -CT (experimental group, internal reference gene)
The Δ CT values for the experimental groups were normalized by the Δ CT values for the control group:
Δ Δ CT ═ Δ CT experimental group- Δ CT control group
Ratio (experimental/control) 2-ΔΔCT
And calculating the obtained value according to a formula, namely the change of the expression level before and after the intervention of the target gene.
4. Results
The experimental result is shown in fig. 2, and the result shows that after the intervention of TMAO on smooth muscle cells, the expression level of inflammation-related factors IL-1, IL-6 and TNF-alpha is increased, the expression level of the inflammation factors of human vascular smooth muscle cells is obviously reduced after the pretreatment of fermentation supernatant of curcumin or Lactobacillus reuteri EHA2 strain alone, and especially the intervention of curcumin and Lactobacillus reuteri supernatant compound obviously can reduce the expression level of the inflammation factors IL-1, IL-6 and TNF-alpha better than the intervention of curcumin alone.
The results show that the curcumin and/or the Lactobacillus reuteri EHA2 strain can eliminate TMAO and inflammation caused by TMAO, has the function of relieving atherosclerotic diseases, and has good social and economic benefits.
Sequence listing
<110> southern medical university
<120> a composition with functions of eliminating trimethylamine oxide and resisting inflammation, a preparation method and applications thereof
<141> 2019-11-14
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1465
<212> DNA
<213> Lactobacillus reuteri EHA2(Lactobacillus reuteri EHA2)
<400> 1
atctgtcgcc ttaggcggct cctccataaa ggttaggcca ccgactttgg gcgttacaaa 60
ctcccatggt gtgacgggcg gtgtgtacaa ggcccgggaa cgtattcacc gcggcatgct 120
gatccgcgat tactagcgat tccgacttcg tgtaggcgag ttgcagccta cagtccgaac 180
tgagaacggc tttaagagat tagcttactc tcgcgagctt gcgactcgtt gtaccgtcca 240
ttgtagcacg tgtgtagccc aggtcataag gggcatgatg atctgacgtc gtccccacct 300
tcctccggtt tgtcaccggc agtctcacta gagtgcccaa cttaatgctg gcaactagta 360
acaagggttg cgctcgttgc gggacttaac ccaacatctc acgacacgag ctgacgacga 420
ccatgcacca cctgtcattg cgtccccgaa gggaacgcct tatctctaag gttagcgcaa 480
gatgtcaaga cctggtaagg ttcttcgcgt agcttcgaat taaaccacat gctccaccgc 540
ttgtgcgggc ccccgtcaat tcctttgagt ttcaaccttg cggtcgtact ccccaggcgg 600
agtgcttaat gcgttagctc cggcactgaa gggcggaaac cctccaacac ctagcactca 660
tcgtttacgg catggactac cagggtatct aatcctgttc gctacccatg ctttcgagcc 720
tcagcgtcag ttgcagacca gacagccgcc ttcgccactg gtgttcttcc atatatctac 780
gcattccacc gctacacatg gagttccact gtcctcttct gcactcaagt cgcccggttt 840
ccgatgcact tcttcggtta agccgaaggc tttcacatca gacctaagca accgcctgcg 900
ctcgctttac gcccaataaa tccggataac gcttgccacc tacgtattac cgcggctgct 960
ggcacgtagt tagccgtgac tttctggttg gataccgtca ctgcgtgaac agttactctc 1020
acgcacgttc ttctccaaca acagagcttt acgagccgaa acccttcttc actcacgcgg 1080
tgttgctcca tcaggcttgc gcccattgtg gaagattccc tactgctgcc tcccgtagga 1140
gtatggaccg tgtctcagtt ccattgtggc cgatcagtct ctcaactcgg ctatgcatca 1200
tcgccttggt aagccgttac cttaccaact agctaatgca ccgcaggtcc atcccagagt 1260
gatagccaaa gccatctttc aaacaaaagc catgtggctt ttgttgttat gcggtattag 1320
catctgtttc caaatgttat cccccgctcc ggggcaggtt acctacgtgt tactcacccg 1380
tccgccactc actggtgatc catcgtcaat caggtgcaag caccatcaat cagttgggcc 1440
agtgcgtacg actgcatgta tagca 1465
Claims (5)
1. The application of the composition containing the curcumin solution and the fermentation supernatant of the lactobacillus reuteri EHA2 strain in the preparation of the preparation with functions of removing trimethylamine oxide and resisting inflammation is characterized in that the lactobacillus reuteri EHA2 strain is preserved in Guangdong province microbial strain preservation center in 2019, 9 and 2 days, and the preservation number is GDMCC NO: 60758.
2. the use according to claim 1, wherein the composition comprises the following components in the following volume ratios: the curcumin solution and fermentation supernatant of lactobacillus reuteri EHA2 strain = 1-3: 1 to 3.
3. The use according to claim 2, wherein the composition comprises the following components in the following volume ratios: curcumin solution and lactobacillus reuteri EHA2 strain fermentation supernatant = 1: 3.
4. the use according to claim 3, wherein the curcumin solution is at a concentration of 40 to 300 mM.
5. The application of any one of claims 2 to 4, wherein the fermentation liquid of the Lactobacillus reuteri EHA2 strain is prepared by activating strains, inoculating the activated strains into a fermentation medium, fermenting at 30-37 ℃ for 40-50 h, adjusting the OD of the fermented liquid to 1.6-1.8, centrifuging, and taking the supernatant to obtain the fermentation supernatant of the Lactobacillus reuteri EHA2 strain.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911114374.5A CN110959862B (en) | 2019-11-14 | 2019-11-14 | Composition with functions of removing trimethylamine oxide and resisting inflammation and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911114374.5A CN110959862B (en) | 2019-11-14 | 2019-11-14 | Composition with functions of removing trimethylamine oxide and resisting inflammation and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110959862A CN110959862A (en) | 2020-04-07 |
| CN110959862B true CN110959862B (en) | 2021-08-13 |
Family
ID=70030715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911114374.5A Active CN110959862B (en) | 2019-11-14 | 2019-11-14 | Composition with functions of removing trimethylamine oxide and resisting inflammation and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110959862B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110974853B (en) * | 2019-12-17 | 2023-06-16 | 南方医科大学 | Anticancer composition based on curcumin and lactobacillus reuteri fermentation supernatant and application thereof |
| CN114410533A (en) * | 2022-01-27 | 2022-04-29 | 江南大学 | Application of lactobacillus reuteri CCFM1040 in relieving and preventing atherosclerosis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101468944A (en) * | 2007-12-24 | 2009-07-01 | 北京琥珀光华医药科技开发有限公司 | Method for extracting and separating turmeric effective ingredient curcumin |
| CN107164274A (en) * | 2017-06-15 | 2017-09-15 | 广州市微生物研究所 | A kind of lactic acid bacteria composite fungicide and its preparation method and application |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019070676A1 (en) * | 2017-10-02 | 2019-04-11 | The Procter & Gamble Company | Methods for inhibiting conversion of choline to trimethylamine (tma) |
-
2019
- 2019-11-14 CN CN201911114374.5A patent/CN110959862B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101468944A (en) * | 2007-12-24 | 2009-07-01 | 北京琥珀光华医药科技开发有限公司 | Method for extracting and separating turmeric effective ingredient curcumin |
| CN107164274A (en) * | 2017-06-15 | 2017-09-15 | 广州市微生物研究所 | A kind of lactic acid bacteria composite fungicide and its preparation method and application |
Non-Patent Citations (3)
| Title |
|---|
| TO ASSESS THE POTENTIAL OF CURCUMIN AGAINST GUT MICROBIOTA-INDUCED ALTERATION IN CHOLINE METABOLISM IN C57BL/6J MICE;HIMANI JOSHI等;《International Journal of Pharmacy and Pharmaceutical Sciences》;20170228;第9卷(第3期);第215-226页 * |
| 姜黄素抗动脉粥样硬化研究进展;阳巍等;《国际病理科学与临床杂志》;20120228;第32卷(第1期);第55页左栏第1段-右栏第1段，第56页第2节 * |
| 阳巍等.姜黄素抗动脉粥样硬化研究进展.《国际病理科学与临床杂志》.2012,第32卷(第1期),第55页左栏第1段-右栏第1段，第56页第2节. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110959862A (en) | 2020-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110656060B (en) | Multi-linked lactobacillus composition and application thereof in female vaginal health | |
| CN103275905B (en) | Lactobacillus rhamnosus CCFM0528 having diabetes preventing effect | |
| CN116024130B (en) | Lactobacillus fermentum A21215 for reducing blood uric acid and application thereof | |
| CN110777087B (en) | Lactobacillus johnsonii and application thereof | |
| CN113832058A (en) | Application of bifidobacterium lactis BLA80 in preparation of medicines or foods for reducing blood fat and regulating intestinal flora | |
| CN110959862B (en) | Composition with functions of removing trimethylamine oxide and resisting inflammation and preparation method and application thereof | |
| CN116083325B (en) | Lactobacillus rhamnosus for improving helicobacter pylori related gastrointestinal diseases and application thereof | |
| CN110713960B (en) | Lactobacillus plantarum LN66 and application thereof in product for reducing halitosis risk | |
| CN112760250B (en) | Rumen lactobacillus for relieving colitis and application thereof | |
| CN115992059B (en) | Lactobacillus johnsonii for producing feruloyl esterase and application thereof in relieving ulcerative colitis | |
| US20230218688A1 (en) | Lactobacillus helveticus zjuids12 for treating alcoholic liver disease and application thereof | |
| WO2018112739A1 (en) | Bifidobacterium pseudocatenulatum, culture method therefor and application thereof | |
| WO2018112741A1 (en) | Lactobacillus acidophilus, culture method therefor and application thereof | |
| CN117106669A (en) | Stenotrophomonas pseudoacidophila capable of improving alcoholic cardiomyopathy and application thereof | |
| CN113797232B (en) | Composition with insulin resistance relieving function and application thereof | |
| CN117736942B (en) | Fermented lactobacillus mucilaginosus JYLF-315 for improving skin aging, and metagen preparation and application thereof | |
| WO2018112740A1 (en) | Lactobacillus gasseri, culture method therefor and application thereof | |
| CN113637603B (en) | Lactobacillus entericus and application thereof | |
| CN111117925A (en) | Anerostipes sp B2131 bacterium and application thereof in inflammatory bowel disease | |
| CN111088181B (en) | Bifidobacterium breve strain BK55 and application thereof in inhibiting clostridium difficile | |
| CN116726056A (en) | Application of lactobacillus plantarum containing ldh gene in preparation of enteritis relieving product | |
| CN115873081A (en) | Lactein and application thereof in prevention and control of bacterial infection of pets | |
| CN111304120B (en) | Application of Blautia sp B2132 bacterium in prevention and/or treatment of inflammatory bowel disease | |
| CN110141583A (en) | A kind of application of Kefir grains lactobacillus M3 in active constituent antibacterial and as treatment type II diabetes medicament | |
| CN110974853B (en) | Anticancer composition based on curcumin and lactobacillus reuteri fermentation supernatant and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |